AVAV's Search Interest Surges: Navigating the SCAR Program News Trend

AVAV Stock Turbulence: Driven by SCAR Program Uncertainty

AVAV shares have experienced dramatic fluctuations, largely fueled by a single, high-profile news event: the Space Force's decision to reopen bidding for the $1.4 billion SCAR contract. This announcement triggered a sharp 17% drop in the stock price. Investor attention has since centered on developments related to "Space Force SCAR rebidding" and "AVAV contract," making the stock highly sensitive to any new updates or official statements.

The volatility has followed a classic pattern. The initial news led to a steep sell-off, with analysts such as Raymond James downgrading the stock and warning that the rebidding could wipe out as much as $1.4 billion from AVAV’s backlog. However, the stock rebounded by 6.5% the following day after the company confirmed it was still actively negotiating with the Space Force for a contract revision. This cycle of sharp moves mirrors the spikes in search interest, with each new development prompting a surge in attention, followed by a lull until the next update.

Currently, the SCAR program is the focal point for both the company and the market. While AVAV emphasizes its competitive edge in delivering advanced systems, investors are fixated on the outcome of the contract. The upcoming earnings call on March 10th is expected to provide the next significant update, but until then, any news about the rebidding process will likely dictate the stock’s direction.

$1.4 Billion at Risk: The Stakes for AVAV

The SCAR rebidding is more than just a headline—it poses a direct threat to AVAV’s financial stability. The contract represents about $1.4 billion in value, and analysts caution that losing it could slash $1 billion to $1.4 billion from the company’s $2.8 billion backlog. As AVAV’s largest program, its loss would halve the backlog and significantly constrain revenue prospects for years to come.

Volatility Expansion Long-Only Strategy: Backtest Overview

• Entry Criteria: Buy AVAV when ATR(14) rises above its 60-day simple moving average and the price closes above the 20-day high.
• Exit Criteria: Sell when ATR(14) falls below its 60-day SMA, after 20 trading days, or if a 15% profit or 10% loss is reached.
• Risk Controls: Take-profit at 15%, stop-loss at 10%, maximum holding period of 20 days.

Backtest Results

• Total Return: 7.11%
• Annualized Return: 5.04%
• Maximum Drawdown: 18.64%
• Profit-Loss Ratio: 1.26
• Total Trades: 4 (2 winners, 2 losers)
• Win Rate: 50%
• Average Holding Period: 8.5 days
• Average Gain: 17.96%
• Average Loss: 12.14%
• Largest Gain: 24.24%
• Largest Loss: 12.43%

Why the Space Force Is Rebidding: Strategic Shifts

The Pentagon’s decision to reopen the SCAR contract stems from a desire to diversify its supplier base. The Space Force aims to bring in additional vendors to enhance manufacturing and supply chain resilience. This move reflects a broader industry shift away from custom, cost-plus contracts toward more competitive, commercialized arrangements. For AVAV, this means its longstanding relationship with the program is under review, and future success will depend on its commercial competitiveness and pricing, not just technical expertise.

The contract’s evolution adds to the uncertainty. Originally structured as a flexible Other Transaction Agreement, it shifted to a cost-plus development deal. Now, with work paused, AVAV is negotiating to move to a firm-fixed-price contract, which would transfer more cost risk to the company. AVAV has invested in expanding its manufacturing capabilities, but the future of that investment now hinges on the SCAR program’s outcome.

Ultimately, the SCAR contract’s resolution will have a binary impact on AVAV’s near-term financial outlook. The potential loss is so significant that it could erase years of backlog growth in a single decision, explaining the extreme volatility in the stock as investors weigh the risk of a major financial setback.

Alternative Growth Stories: New Contracts and Expansion

Despite the SCAR program dominating headlines, AVAV is working to shift the narrative by securing new contracts and investing in production capacity. In late February, the company landed a $186 million order from the U.S. Army for its upgraded Switchblade loitering munitions. This marks the Army’s first purchase of the new model, reinforcing AVAV’s position as a key supplier of advanced weaponry. As a result, investor interest may soon pivot to terms like “Switchblade 600 Block 2 order” or “Army loitering munitions contract.”

AVAV is also making significant investments to scale up its manufacturing, particularly in Albuquerque, New Mexico, to support its Space and Directed Energy platforms. While this expansion is closely linked to the SCAR program, it also signals confidence in broader demand. The company’s focus is on execution and speed to market, which could give it an edge as the government shifts toward fixed-price, commercial contracts.

Analyst opinions reflect this dual narrative. Piper Sandler, for example, recently reduced its price target from $391 to $290—still suggesting 39% upside—based on AVAV’s long-term prospects rather than the immediate SCAR risk. The firm’s “overweight” rating highlights operational achievements and manufacturing growth as reasons for optimism, even amid contract uncertainty.

In summary, AVAV is balancing two competing stories. The SCAR program remains the main source of market anxiety, but the new Army contract and manufacturing expansion offer alternative growth drivers. While the market’s attention is currently fixed on the contract risk, these operational wins could provide support if SCAR-related uncertainty continues.

Key Catalysts Ahead: What Investors Should Monitor

AVAV’s stock will likely remain volatile in the near term, with several important events on the horizon. The immediate focus is on the outcome of SCAR contract negotiations. The company’s confirmation that it is in active talks with the Space Force for a firm-fixed-price deal is the current narrative. A successful agreement would likely stabilize the stock and clarify the path forward. Investors are also watching for any official updates on the rebidding timeline or contractor selection, which could trigger another surge in attention and serve as a decisive catalyst.

The company’s Q4 earnings report, scheduled for March 10th, is another crucial milestone. This update will provide fresh backlog data and management’s perspective on the SCAR situation, helping investors gauge the potential financial impact. Given the recent analyst downgrade and the $1.4 billion at stake, this report will be pivotal for setting expectations for the remainder of the year.

Beyond the SCAR contract, developments related to the $186 million Army Switchblade order and progress on the Albuquerque manufacturing expansion are also worth tracking. These factors could help support the stock if uncertainty around the SCAR program persists. For now, however, the market remains laser-focused on the contract negotiations, and AVAV’s share price is likely to continue reacting sharply to each new headline.